GO:0062069 GARP complex binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0062069 (GARP complex binding) is a molecular function defined as binding to a GARP complex, the Golgi-associated retrograde protein (GARP) complex.
• The GARP complex is a tethering complex that mediates retrograde transport from endosomes to the trans-Golgi network (TGN) and is conserved from yeast to humans.
• Proteins that bind the GARP complex include ARMH3, an ARL5 effector that promotes PI4KB-catalyzed PI4P synthesis at the TGN.
• GARP complex binding is linked to cellular processes such as dendrite remodeling, where the GARP complex prevents sterol accumulation at the TGN.
• Dysregulation of GARP complex-related pathways is implicated in cancer, immune tolerance, and neurological disorders [4,6,8].
• Research on GARP complex binding uses CRISPR knockout, knock-in, overexpression, and advanced imaging and proteomics methods [2,3].
Description
GO:0062069, GARP complex binding, is a molecular function term in the Gene Ontology that describes the selective interaction of a protein with the Golgi-associated retrograde protein (GARP) complex. The GARP complex is a multisubunit tethering complex that orchestrates retrograde vesicle transport from endosomes to the trans-Golgi network (TGN), a process essential for maintaining organelle homeostasis and protein sorting. Proteins that bind the GARP complex often act as effectors or regulators, such as ARMH3, which links ARL5 GTPase signaling to PI4KB-mediated phosphatidylinositol 4-phosphate (PI4P) synthesis at the TGN. Understanding GARP complex binding is therefore critical for dissecting membrane trafficking, signaling, and disease mechanisms. The GARP complex itself is composed of four subunits (VPS51, VPS52, VPS53, and VPS54) and is recruited to membranes by Rab GTPases and other cofactors. Binding partners of the GARP complex can modulate its tethering activity, coordinate lipid metabolism, and influence downstream pathways such as TGF-β signaling [1,4]. For example, the GARP complex is known to interact with the latent TGF-β complex, and this interaction is targeted in cancer immunotherapy [4,5]. Thus, GARP complex binding represents a hub for integrating vesicle trafficking with cell signaling and immune regulation. Researchers studying GARP complex binding aim to identify new binding proteins, map interaction interfaces, and determine how these interactions affect cellular functions in health and disease [2,3]. This article provides a comprehensive overview of the molecular mechanisms, key genes, disease associations, and experimental models relevant to GO:0062069, with a focus on CRISPR-based approaches for functional validation.
GARP complex binding At A Glance
| GO ID | GO:0062069 |
|---|---|
| GO term | GARP complex binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to the GARP complex, a tethering complex that mediates retrograde transport from endosomes to the trans-Golgi network. |
| Related cellular component | GARP complex (Golgi-associated retrograde protein complex) |
| Related biological process | Retrograde vesicle-mediated transport, Golgi to endosome; dendrite remodeling |
| Example binding protein | ARMH3, an ARL5 effector that promotes PI4KB-catalyzed PI4P synthesis at the TGN |
| Disease relevance | Cancer, immune tolerance, neurological disorders [4,6,8] |
What Is GO:0062069?
GARP complex binding (GO:0062069) is defined as the molecular function of selectively interacting with a GARP complex. In other words, it is the binding activity of a protein or biomolecule to the Golgi-associated retrograde protein (GARP) complex, a multisubunit tethering complex involved in retrograde transport at the trans-Golgi network.
Why Is GARP complex binding Important in Cell Biology?
GARP complex binding is important because it regulates the recruitment and activity of the GARP complex, which is essential for retrograde membrane trafficking, organelle homeostasis, and cell signaling. Disruption of GARP complex interactions can lead to defects in dendrite remodeling, sterol accumulation at the TGN, and altered TGF-β signaling, with implications for cancer, immune disorders, and neurodegeneration [3,4,6]. Targeting GARP complex binding partners, such as the GARP:TGF-β1 complex, has emerged as a therapeutic strategy in oncology [5,7].
• Regulates retrograde transport from endosomes to the trans-Golgi network, a fundamental cellular process.
• Controls lipid homeostasis at the TGN, including sterol distribution during dendrite remodeling.
• Modulates TGF-β signaling through interactions with latent TGF-β complexes [1,4].
• Influences immune tolerance mediated by B lymphocytes via cell surface GARP-TGF-β complexes.
• Implicated in cancer progression and metastasis, particularly in breast cancer and tumor microenvironment [4,6].
• Potential target for immunotherapy: anti-GARP:TGF-β1 antibodies are in clinical trials [5,7].
• Required for proper neuronal development and function.
• Provides a molecular link between ARL5 GTPase signaling and PI4P synthesis at the TGN.
• Offers opportunities for CRISPR-based functional studies to dissect gene-disease causality [2,3].
• Enables development of targeted therapies for diseases caused by deleterious T cell activity.
What Happens During GARP complex binding?
Recruitment of GARP complex to membranes
In simple terms: The GARP complex is brought to the right place in the cell by binding to other proteins and lipids.
The GARP complex is recruited to the trans-Golgi network (TGN) and endosomal membranes through interactions with Rab GTPases and other cofactors. Binding partners such as ARMH3 act as effectors that link ARL5 GTPase to the GARP complex, facilitating its localization and function. This recruitment is essential for subsequent tethering events.
Tethering of vesicles to the TGN
In simple terms: The GARP complex acts like a molecular hook that catches vesicles and pulls them to the TGN.
Once at the membrane, the GARP complex binds to vesicles carrying retrograde cargo, tethering them to the TGN. This tethering is a prerequisite for SNARE-mediated fusion. Proteins that bind the GARP complex can modulate its tethering activity, ensuring efficient transport.
Regulation of lipid metabolism at the TGN
In simple terms: GARP complex binding helps control the distribution of fats in the cell's sorting station.
The GARP complex prevents sterol accumulation at the TGN during dendrite remodeling, and binding partners like ARMH3 promote PI4KB-catalyzed PI4P synthesis, which is critical for membrane identity and trafficking [2,3]. This highlights a role for GARP complex binding in lipid homeostasis.
Integration with signaling pathways
In simple terms: GARP complex binding connects vesicle traffic with cell signaling, including immune and growth signals.
The GARP complex interacts with latent TGF-β complexes, and binding proteins can influence TGF-β activation. This crosstalk is relevant in immune tolerance and cancer, where GARP-TGF-β complexes on B cells and regulatory T cells suppress immune responses [4,8]. Antibodies targeting the GARP:TGF-β1 complex are being developed for cancer therapy [5,7].
Key Genes Involved in GO:0062069 GARP complex binding
The following genes encode proteins that bind the GARP complex or are core subunits and regulators of GARP complex function, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VPS51 | Core subunit of GARP complex | Essential for retrograde transport; mutations linked to developmental defects |
| VPS52 | Core subunit of GARP complex | Required for tethering; implicated in Golgi homeostasis |
| VPS53 | Core subunit of GARP complex | Mutations cause pontocerebellar hypoplasia; involved in dendrite remodeling |
| VPS54 | Core subunit of GARP complex | Wobbler mouse model; motor neuron degeneration |
| ARMH3 | ARL5 effector, promotes PI4KB-catalyzed PI4P synthesis at TGN | Links ARL5 signaling to GARP complex function |
| ARL5 | Small GTPase that recruits ARMH3 | Regulates GARP complex binding and TGN lipid metabolism |
| PI4KB | Phosphatidylinositol 4-kinase beta | Synthesizes PI4P at TGN; regulated by ARMH3-GARP axis |
| LRRC32 (GARP) | Latent TGF-β binding protein | Forms GARP-TGF-β complex; target for cancer immunotherapy [4,5,6] |
| LTBP1 | Latent TGF-β binding protein | Interacts with GARP complex; modulates TGF-β activation |
| LTBP3 | Latent TGF-β binding protein | Similar to LTBP1; involved in TGF-β signaling |
| TGFB1 | Transforming growth factor beta 1 | Cytokine activated by GARP complex binding; immunosuppressive [4,7] |
| VPS50 | Subunit of GARP complex | Required for retrograde transport; interacts with VPS51 |
| VPS53 | Subunit of GARP complex | Mutations cause pontocerebellar hypoplasia; involved in dendrite remodeling |
| RAB6 | GTPase involved in Golgi transport | May cooperate with GARP complex in retrograde trafficking |
| COG complex | Conserved oligomeric Golgi complex | Interacts with GARP complex for vesicle tethering |
| STX6 | Syntaxin 6, SNARE protein | Participates in fusion at TGN; may bind GARP complex |
| VTI1A | SNARE protein | Involved in retrograde transport; potential GARP interactor |
How Is GARP complex binding Regulated?
GARP complex binding is regulated by small GTPases such as ARL5, which recruits effector proteins like ARMH3 to promote PI4KB-catalyzed PI4P synthesis at the TGN. Additionally, the GARP complex itself is regulated by Rab GTPases and phosphorylation events that control its membrane recruitment and activity. In immune cells, the formation of GARP-TGF-β complexes is modulated by lysosomal metabolism, and suppression of lysosome-mediated GARP/TGF-β1 complexes can deplete regulatory T cells. Antibody-mediated targeting of the GARP:TGF-β1 complex can also modulate TGF-β1 activation, highlighting extracellular regulation.
GARP complex binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LRRC32 (GARP) | Cancer, immune tolerance | Knockout mice, syngeneic tumor models [4,6] |
| VPS53 | Pontocerebellar hypoplasia, neurodevelopmental disorders | Patient-derived iPSCs, knockout zebrafish |
| VPS54 | Motor neuron degeneration (wobbler mouse) | Vps54 mutant mice, motor neuron cultures |
| TGFB1 | Cancer, fibrosis, autoimmune diseases | Conditional knockout mice, TGF-β reporter cells [1,7] |
| ARMH3 | Golgi homeostasis, potential cancer link | CRISPR knockout cell lines, PI4P imaging |
Cancer and tumor microenvironment
GARP complex binding is implicated in cancer through the GARP-TGF-β axis. The GARP complex presents latent TGF-β on the surface of regulatory T cells and B cells, contributing to immune suppression in the tumor microenvironment [4,8]. Selective targeting of the GARP-LTGFβ axis augments PD-1 blockade by enhancing CD8+ T cell antitumor immunity. Suppression of lysosome metabolism-mediated GARP/TGF-β1 complexes specifically depletes regulatory T cells and inhibits breast cancer metastasis. Clinical trials with livmoniplimab, an antibody targeting the GARP:TGF-β1 complex, are ongoing in advanced solid tumors.
Neurological disorders
The GARP complex is essential for dendrite remodeling, and its dysfunction leads to sterol accumulation at the trans-Golgi network, contributing to neuronal defects. Mutations in GARP subunits such as VPS53 are associated with pontocerebellar hypoplasia, a severe neurodevelopmental disorder. The wobbler mouse, which has a mutation in Vps54, exhibits motor neuron degeneration, providing a model for GARP-related neurodegeneration.
Immune tolerance and autoimmunity
B lymphocytes confer immune tolerance via cell surface GARP-TGF-β complex, and disruption of this interaction can lead to autoimmunity. Antibody-mediated TGF-β1 activation is being explored for diseases caused by deleterious T cell activity, such as autoimmune conditions. Thus, GARP complex binding is a key regulator of immune homeostasis.
From GARP complex binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GARP complex binding affect retrograde transport? | CRISPR knockout of VPS51/VPS52/VPS53/VPS54 in HeLa or HEK293 cells |
| How does a point mutation in a binding partner alter interaction with GARP? | Point-mutation knock-in via CRISPR in ARMH3 or LRRC32 [2,4] |
| What is the effect of tagging endogenous GARP subunits on localization? | Knock-in of fluorescent tags (e.g., GFP) at VPS52 locus |
| Can overexpression of GARP complex binding protein rescue a phenotype? | Overexpression of ARMH3 or LRRC32 in knockout background [2,6] |
| Which genes are essential for GARP complex binding in immune cells? | CRISPR library screening in primary T cells or B cells [4,8] |
| How does GARP complex binding regulate TGF-β activation? | Knock-in of TGF-β reporter in cancer cell lines [1,7] |
How to Study the GARP complex binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Affinity purification-mass spectrometry (AP-MS) | Protein-protein interactions | Identify GARP complex binding partners |
| Proximity labeling (BioID) | Proximity-based interactome | Map GARP interactors in live cells |
| Fluorescence microscopy | Localization and dynamics | Visualize GARP at TGN and sterol accumulation |
| CRISPR knockout screens | Gene essentiality and function | Discover regulators of GARP binding [4,8] |
| Surface plasmon resonance (SPR) | Binding affinity and kinetics | Validate direct GARP interactions |
| Isothermal titration calorimetry (ITC) | Thermodynamics of binding | Quantify GARP binding affinity |
| PI4P biosensor imaging | Lipid distribution | Monitor PI4P synthesis at TGN |
| TGF-β reporter assays | TGF-β activation | Assess GARP-TGF-β complex function [1,7] |
Proteomic identification of GARP complex binding partners
Affinity purification coupled with mass spectrometry (AP-MS) can identify proteins that bind the GARP complex. For example, ARMH3 was identified as an ARL5 effector that interacts with the GARP complex and promotes PI4KB-catalyzed PI4P synthesis. Proximity labeling methods such as BioID can also map GARP interactors in living cells.
Imaging-based assays for GARP complex localization and function
Fluorescence microscopy, including live-cell imaging of GFP-tagged GARP subunits, allows visualization of GARP complex dynamics at the TGN. This approach revealed that the GARP complex prevents sterol accumulation at the TGN during dendrite remodeling. PI4P sensors can be used to monitor lipid changes upon GARP complex binding.
Functional genomics with CRISPR screens
Genome-wide CRISPR knockout screens can identify genes required for GARP complex binding or GARP-mediated processes. Such screens have been used to uncover regulators of TGF-β signaling and immune tolerance [4,8]. Focused CRISPR libraries targeting trafficking genes can pinpoint novel binding partners.
Biochemical assays for binding affinity and kinetics
Recombinant GARP complex subunits and candidate binding proteins can be used in surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) to measure binding affinities. These methods help validate direct interactions and map binding interfaces.
How CRISPR Can Be Used to Study GO:0062069 GARP complex binding
Knockout
CRISPR knockout of GARP complex subunits (VPS51, VPS52, VPS53, VPS54) or binding partners (ARMH3, LRRC32) can abolish GARP complex binding and reveal downstream effects on retrograde transport, lipid homeostasis, and signaling [2,3]. For example, VPS53 knockout leads to sterol accumulation at the TGN and defects in dendrite remodeling.
Point Mutation
Point mutations can be introduced into genes encoding GARP complex binding proteins to disrupt specific interaction interfaces. For instance, mutations in ARMH3 that impair ARL5 binding can be generated to study the ARL5-ARMH3-GARP axis. Similarly, point mutations in LRRC32 can affect GARP-TGF-β complex formation.
Knock-in
Knock-in of epitope tags (e.g., GFP, HA) or fluorescent proteins at endogenous loci allows visualization and purification of GARP complex binding proteins. Tagged VPS52 or ARMH3 can be used for live-cell imaging and proteomics [2,3]. Knock-in of disease-associated mutations (e.g., in VPS53) can model neurological disorders.
Overexpression
Overexpression of GARP complex binding proteins such as ARMH3 or LRRC32 can enhance GARP complex function or TGF-β presentation. This approach is useful for rescue experiments and for studying gain-of-function effects in cancer and immune cells [2,6].
How EDITGENE Supports GARP complex binding Research
Researchers studying GARP complex binding-related genes often need to determine whether a candidate gene is causally involved in trafficking, signaling, or disease. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this discovery, from gene knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for GARP complex binding research.
Frequently Asked Questions About GARP complex binding
What is GO:0062069?
GO:0062069 is the Gene Ontology molecular function term for GARP complex binding, defined as binding to a GARP complex.
What is the GARP complex?
The GARP complex (Golgi-associated retrograde protein complex) is a multisubunit tethering complex that mediates retrograde transport from endosomes to the trans-Golgi network.
What genes are involved in GARP complex binding?
Genes include VPS51, VPS52, VPS53, VPS54 (core subunits), ARMH3, ARL5, PI4KB, LRRC32 (GARP), and TGFB1 [2,3,4].
How is GARP complex binding studied?
It is studied using affinity purification-mass spectrometry, proximity labeling, fluorescence microscopy, CRISPR screens, and biochemical binding assays [2,3].
What diseases are associated with GARP complex binding?
Diseases include cancer, immune tolerance disorders, and neurological conditions such as pontocerebellar hypoplasia [3,4,6].
What is the role of ARMH3 in GARP complex binding?
ARMH3 is an ARL5 effector that promotes PI4KB-catalyzed PI4P synthesis at the trans-Golgi network, linking ARL5 signaling to GARP complex function.
How does the GARP complex regulate TGF-β signaling?
The GARP complex binds latent TGF-β and presents it on the cell surface, contributing to immune suppression; targeting this interaction is a therapeutic strategy [4,5,8].
Can CRISPR be used to study GARP complex binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect GARP complex binding and its downstream effects [2,3].
What is the clinical relevance of GARP:TGF-β1 complex?
Antibodies targeting the GARP:TGF-β1 complex, such as livmoniplimab, are in clinical trials for advanced solid tumors.
What model organisms are used to study GARP complex binding?
Model organisms include mice (e.g., wobbler mouse with Vps54 mutation), zebrafish, and patient-derived iPSCs.
Conclusion
GARP complex binding (GO:0062069) is a critical molecular function that governs retrograde membrane trafficking, lipid homeostasis, and signaling at the trans-Golgi network. Its dysregulation is linked to cancer, immune disorders, and neurodegeneration, making it a promising target for therapeutic intervention [3,4,6]. Continued research using CRISPR-based models and advanced proteomics will further illuminate the mechanisms and disease relevance of GARP complex binding.
References
- 1. Jin M et al.. 2024. Dynamic allostery drives autocrine and paracrine TGF-β signaling.. Cell 187(22):6200-6219.e23 PMID: 39288764
- 2. Ishida M et al.. 2024. ARMH3 is an ARL5 effector that promotes PI4KB-catalyzed PI4P synthesis at the trans-Golgi network.. Nat Commun 15(1):10168 PMID: 39580461
- 3. O'Brien CE et al.. 2023. The GARP complex prevents sterol accumulation at the trans-Golgi network during dendrite remodeling.. J Cell Biol 222(1) PMID: 36239632
- 4. Li A et al.. 2022. Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8(+) T cell antitumor immunity.. J Immunother Cancer 10(9) PMID: 36096533
- 5. Shimizu T et al.. 2024. First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.. Front Oncol 14:1376551 PMID: 39534099
- 6. Ma J et al.. 2024. Suppression of lysosome metabolism-meditated GARP/TGF-β1 complexes specifically depletes regulatory T cells to inhibit breast cancer metastasis.. Oncogene 43(25):1930-1940 PMID: 38698265
- 7. Lambert F et al.. 2025. Antibody-mediated TGF-β1 activation for the treatment of diseases caused by deleterious T cell activity.. Cell Rep 44(8):116061 PMID: 40742810
- 8. Wallace CH et al.. 2018. B lymphocytes confer immune tolerance via cell surface GARP-TGF-β complex.. JCI Insight 3(7) PMID: 29618665
